The subscription provides a welcome boost to Summit’s near-term plans to initiate Phase III trials for ridinilazole, the company’s novel treatment of C. difficile infection, in Q1 2019; and supports the completion of IND enabling studies for SMT-571 for the treatment of gonorrhoea, expected to enter Phase I trials in H2 2019. We reiterate our positive stance on Summit.
18 Dec 2018
Proposed subscription to raise $25m boosts cash runway to early 2020
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Proposed subscription to raise $25m boosts cash runway to early 2020
Summit Therapeutics Inc (SMMT:NAS) | 0 0 0.0%
- Published:
18 Dec 2018 -
Author:
Jens Lindqvist -
Pages:
3
The subscription provides a welcome boost to Summit’s near-term plans to initiate Phase III trials for ridinilazole, the company’s novel treatment of C. difficile infection, in Q1 2019; and supports the completion of IND enabling studies for SMT-571 for the treatment of gonorrhoea, expected to enter Phase I trials in H2 2019. We reiterate our positive stance on Summit.